Influence of obesity in critical illness patients at Serum Levels of vancomycin with continuous application

Influence of obesity in critical illness patients at Serum Levels of vancomycin with continuous application - AdipoVANC

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00011176

Enrollment

1700

Registered

2017-11-27

Start date

2016-12-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

A41 E66

Interventions

Group 1: normal weight patients ( BMI = 18,5 und < 30 kg/m²) at ICU with continuou application of vancomycin: retrospective analysis of the years 2009 - 2016 (demographics, serum levels of vancomycin

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: treatment at ICU with infection (clinical suspected or with microbiological cultures) continuous application of vancomycin Age not less than 18 between 2009 and 2016

Exclusion criteria

Exclusion criteria: BMI < 18.5 kg/m2

Design outcomes

Primary

Measure	Time frame
number of treatment days with serum level below the minimum of target of vancomycin (serum level <20mg/L)	—

Secondary

Measure	Time frame
incidence of Dosis changing Duration until reaching the target levels incidence of overdosing mortality at day 28,90, at discharge from intensive care unit and hospital SAPS II (simplified acute physiology) and SOFA-score (sequential organ failure assessment) incidence of acute kidney injury days without renal replacement therapy Ventilator free days	—

Countries

Germany

Contacts

Public ContactPhilipp Simon

Klinik und Poliklinik für Anästhesiologie und Intensivtherapie, Universitätsklinikum Leipzig, AöR

philipp.simon@medizin.uni-leipzig.de03419717700

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026